Zao Ren An Shen capsule for insomnia: a double-blind, randomized, placebo-controlled trial.


Journal

Sleep
ISSN: 1550-9109
Titre abrégé: Sleep
Pays: United States
ID NLM: 7809084

Informations de publication

Date de publication:
14 02 2022
Historique:
received: 14 09 2021
revised: 22 10 2021
pubmed: 18 11 2021
medline: 18 3 2022
entrez: 17 11 2021
Statut: ppublish

Résumé

The aim of this study was to test the efficacy and safety of Zao Ren An Shen (ZRAS) capsule, a Chinese herbal medicine product, for the treatment of insomnia. We conducted a double-blind randomized placebo-controlled trial. After a one-week placebo run-in, a total of 85 people with insomnia were randomly allocated to receive ZRAS or placebo for 4 weeks. The primary outcomes were insomnia severity assessed with the Insomnia Severity Index (ISI) and the number of participants with adverse events (AEs). Secondary outcomes included objective and subjective sleep parameters, psychological status, fatigue level, quality of life, acceptability, and tolerability. A nonsignificant (p > .05) difference of 0.7 points in ISI in favor of ZRAS capsule was found at the end of the treatment. The number of participants with AEs was not significantly different (p > .05) between the two groups. Except for subjective sleep onset latency, which had a nonsignificant (p > .05) medium effect (Cohen's d = 0.5), the effects in secondary efficacy outcomes were all small (Cohen's d < .4) and nonsignificant (p > .05). The acceptability and tolerability were high in the active group. ZRAS capsule is safe, acceptable, and tolerable, yet not more effective than placebo in the treatment of insomnia. As previous evidence showed that Chinese herbal medicine was effective for insomnia, these results may be explained by the dose of the product, which was lower than the dose generally used in the clinic.Registration: This clinical trial was registered in Australia New Zealand Clinical Trial Registry (registration number ACTRN12619000140156) under the name "Impact of Zao Ren An Shen (ZRAS) capsule on chronic insomnia patients' insomnia severity: A randomized-controlled trial" (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376730&isReview=true).

Identifiants

pubmed: 34788454
pii: 6425938
doi: 10.1093/sleep/zsab266
pii:
doi:

Banques de données

ANZCTR
['ACTRN12619000140156']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Yoann Birling (Y)

NICM Health Research Institute, Western Sydney University, Penrith, NSW, Australia.

Xiaoshu Zhu (X)

NICM Health Research Institute, Western Sydney University, Penrith, NSW, Australia.
School of Health Sciences, NICM Health Research Institute, Western Sydney University, Penrith, NSW, Australia.

Nicole Avard (N)

NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia.

Caterina Tannous (C)

School of Health Sciences, Western Sydney University, Penrith, NSW, Australia.

Paul P Fahey (PP)

School of Health Sciences, Western Sydney University, Penrith, NSW, Australia.

Jerome Sarris (J)

NICM Health Research Institute, Western Sydney University, Penrith, NSW, Australia.
The Florey Institute of Neuroscience and Mental Health and Professional Unit, The Melbourne Clinic, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia.

Alan Bensoussan (A)

NICM Health Research Institute, Western Sydney University, Penrith, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH